Skip to main content
Erschienen in: Annals of Surgical Oncology 11/2018

23.07.2018 | Endocrine Tumors

Differences in the Impact of Age on Mortality in Well-Differentiated Thyroid Cancer

verfasst von: Huan Yan, MD, David J. Winchester, MD, Richard A. Prinz, MD, Chi-Hsiung Wang, PhD, Yoko Nakazato, MD, Tricia A. Moo-Young, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Well-differentiated thyroid cancer (WDTC) is unique in that patient age is part of staging. Several studies have shown a need to increase the age threshold in staging for WDTC, but the separate impact of age on prognosis for papillary and follicular carcinomas has not been examined. We hypothesize that age impacts survival differently for papillary and follicular carcinomas.

Methods

Patients with invasive papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) between 2004 and 2013 were identified in the National Cancer Database, and were stratified by histologic type. Overall survival (OS) was analyzed using multivariable Cox regression, and the Youden index was used to find the optimal age threshold for both histologies.

Results

A total of 204,139 patients with WDTC were identified. Ninety-two percent had PTC, while 7.7% had FTC. The average age was 48.4 years and OS was 96.3%, with a median follow-up of 52.7 months. When analyzing age in 5-year increments, 10-year mortality increased incrementally by 30–50% per age group for PTC, from age < 35 to ≥ 70 years, without an obvious inflection point. However, FTC patients experienced a more than threefold increase in 10-year mortality from age 40–44 years (2.5%) to age 45–49 years (7.9%). The same pattern was found on multivariable Cox regression. The Youden index found the optimal age thresholds were 58.5 years for PTC and 46.2 years for FTC.

Conclusion

OS for PTC decreases incrementally with age, but OS for FTC decreases significantly in patients aged 45 years and older. A higher age threshold may inappropriately downstage some high-risk follicular cancer patients.
Literatur
1.
Zurück zum Zitat Haymart MR. Understanding the relationship between age and thyroid cancer. Oncologist. 2009;14(3):216–21.CrossRef Haymart MR. Understanding the relationship between age and thyroid cancer. Oncologist. 2009;14(3):216–21.CrossRef
2.
Zurück zum Zitat Ganly I, Nixon IJ, Wang LY, Palmer FL, Migliacci JC, Aniss A, et al. Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid. 2015;25(10):1106–14.CrossRef Ganly I, Nixon IJ, Wang LY, Palmer FL, Migliacci JC, Aniss A, et al. Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid. 2015;25(10):1106–14.CrossRef
3.
Zurück zum Zitat Hendrickson-Rebizant J, Sigvaldason H, Nason RW, Pathak KA. Identifying the most appropriate age threshold for TNM stage grouping of well-differentiated thyroid cancer. Eur J Surg Oncol. 2015;41(8):1028–32.CrossRef Hendrickson-Rebizant J, Sigvaldason H, Nason RW, Pathak KA. Identifying the most appropriate age threshold for TNM stage grouping of well-differentiated thyroid cancer. Eur J Surg Oncol. 2015;41(8):1028–32.CrossRef
4.
Zurück zum Zitat Kim S, Myong JP, Suh H, Lee KE, Youn Y-K. Optimal cutoff age for predicting mortality associated with differentiated thyroid cancer. Soares P, ed. PLoS One. 2015;10(6):e0130848.CrossRef Kim S, Myong JP, Suh H, Lee KE, Youn Y-K. Optimal cutoff age for predicting mortality associated with differentiated thyroid cancer. Soares P, ed. PLoS One. 2015;10(6):e0130848.CrossRef
5.
Zurück zum Zitat Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid. 2016;26(3):373–80.CrossRef Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid. 2016;26(3):373–80.CrossRef
6.
Zurück zum Zitat Kim M, Kim WG, Oh HS, Park S, Kwon H, Song DE, et al. Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer. Thyroid. 2017;27(9):1149–1155.CrossRef Kim M, Kim WG, Oh HS, Park S, Kwon H, Song DE, et al. Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer. Thyroid. 2017;27(9):1149–1155.CrossRef
7.
Zurück zum Zitat Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103(11):2269–73.CrossRef Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103(11):2269–73.CrossRef
8.
Zurück zum Zitat Aboelnaga EM, Ahmed RA. Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution. Cancer Biol Med. 2015;12(1):53–9.PubMedPubMedCentral Aboelnaga EM, Ahmed RA. Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution. Cancer Biol Med. 2015;12(1):53–9.PubMedPubMedCentral
9.
Zurück zum Zitat Sugino K, Kameyama K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa, K, et al. Prognosis of follicular thyroid carcinoma. 内分泌甲状腺外会志 2013;30 (1):7–12. Sugino K, Kameyama K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa, K, et al. Prognosis of follicular thyroid carcinoma. 内分泌甲状腺外会志 2013;30 (1):7–12.
10.
Zurück zum Zitat Ito Y, Hirokawa M, Masuoka H, Yabuta T, Kihara M, Higashiyama T, et al. Prognostic factors of minimally invasive follicular thyroid carcinoma: extensive vascular invasion significantly affects patient prognosis. Endocr J. 2013;60(5):637–42.CrossRef Ito Y, Hirokawa M, Masuoka H, Yabuta T, Kihara M, Higashiyama T, et al. Prognostic factors of minimally invasive follicular thyroid carcinoma: extensive vascular invasion significantly affects patient prognosis. Endocr J. 2013;60(5):637–42.CrossRef
11.
Zurück zum Zitat Adam MA, Thomas S, Hyslop T, Scheri RP, Roman SA, Sosa JA Exploring the relationship between patient age and cancer-specific survival in papillary thyroid cancer: rethinking current staging systems. J Clin Oncol. 2016;34(36):4415–4420.CrossRef Adam MA, Thomas S, Hyslop T, Scheri RP, Roman SA, Sosa JA Exploring the relationship between patient age and cancer-specific survival in papillary thyroid cancer: rethinking current staging systems. J Clin Oncol. 2016;34(36):4415–4420.CrossRef
12.
Zurück zum Zitat Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–5.CrossRef Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–5.CrossRef
13.
Zurück zum Zitat Ito Y, Fukushima M, Yabuta T, Tomoda C, Inoue H, Kihara M, et al. Local prognosis of patients with papillary thyroid carcinoma who were intra-operatively diagnosed as having minimal invasion of the trachea: a 17-year experience in a single institute. Asian J Surg. 2009;32(2):102–8.CrossRef Ito Y, Fukushima M, Yabuta T, Tomoda C, Inoue H, Kihara M, et al. Local prognosis of patients with papillary thyroid carcinoma who were intra-operatively diagnosed as having minimal invasion of the trachea: a 17-year experience in a single institute. Asian J Surg. 2009;32(2):102–8.CrossRef
14.
Zurück zum Zitat Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst. 2002;94(3):167–73.CrossRef Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst. 2002;94(3):167–73.CrossRef
Metadaten
Titel
Differences in the Impact of Age on Mortality in Well-Differentiated Thyroid Cancer
verfasst von
Huan Yan, MD
David J. Winchester, MD
Richard A. Prinz, MD
Chi-Hsiung Wang, PhD
Yoko Nakazato, MD
Tricia A. Moo-Young, MD
Publikationsdatum
23.07.2018
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6668-2

Weitere Artikel der Ausgabe 11/2018

Annals of Surgical Oncology 11/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.